ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

1 April 2014

German drug major Bayer (BAYN: DE) presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials at the American College of Cardiology’s 63rd Annual Scientific Session for its oral anticoagulant Xarelto (rivaroxaban).

The company said that as the use of Xarelto continues to grow across a broad range of venous and arterial thromboembolic (VAT) disorders, these data insights help to address unanswered questions that are being faced in daily clinical practice. This included insights into patients with non-valvular atrial fibrillation (AF), obese patients and those on Warfarin.

Initiates two new Phase III trials

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK